Is ramipril safe for use during breastfeeding?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ramipril Should Not Be Used During Breastfeeding

Ramipril is not recommended for breastfeeding mothers and should be avoided. The FDA drug label explicitly states "do not use ramipril in nursing mothers" 1, and this contraindication should guide clinical decision-making despite limited milk transfer data.

Why Ramipril Is Contraindicated

The FDA label provides clear guidance: while a single 10 mg dose resulted in undetectable amounts in breast milk, multiple doses may produce unpredictable low milk concentrations 1. This uncertainty, combined with theoretical concerns about infant hypotension (particularly in premature infants), makes ramipril unsuitable for lactation 2.

Preferred Alternatives for Hypertension During Breastfeeding

Based on the most recent 2025 Circulation guidelines and 2020 Hypertension Canada recommendations, the following agents are safe and effective:

First-Line Options (Safe with Low RID):

  • Enalapril (RID 1.1%) - specifically recommended as safe ACE inhibitor alternative 3, 2
  • Captopril - also listed as safe ACE inhibitor option 2
  • Nifedipine XL (RID 2.3%-3.4%) 3
  • Labetalol (RID 3.6%) 3, 2
  • Amlodipine (RID 1.7%-4.3%) 3

Important Clinical Nuances:

ACE Inhibitors in Lactation: While ramipril specifically is contraindicated, other ACE inhibitors like enalapril and captopril are considered safe with low breast milk concentrations 3, 2. Recent 2025 data on lisinopril showed minimal transfer (RID 0.06%) 4, supporting the safety profile of this drug class when appropriate agents are selected.

Theoretical Concerns: There remains a theoretical risk of hypotension with ACE inhibitors, particularly in premature infants 2. However, this has not been demonstrated clinically with recommended agents like enalapril and captopril.

Beta-Blockers: These are protein-bound with minimal milk transfer, though neonatal heart rate monitoring may be warranted 2.

Common Pitfalls to Avoid

  1. Don't assume all ACE inhibitors are equivalent - ramipril has specific FDA contraindication for nursing, while enalapril and captopril are recommended alternatives
  2. Don't use lisinopril as first choice - despite recent favorable data 4, it has "limited safety data" per guidelines 3, whereas enalapril has established safety
  3. Avoid high-dose thiazides (>25 mg/day hydrochlorothiazide) - may decrease milk production 3

Practical Management Algorithm

  1. If patient is on ramipril during pregnancy: Switch to enalapril or captopril before delivery or immediately postpartum
  2. If inadequate BP control on single agent: Add nifedipine XL or labetalol rather than increasing to potentially problematic doses
  3. Monitor infant for: Adequate feeding, normal activity level (no excessive drowsiness suggesting hypotension)
  4. Target BP: <140/90 mmHg in postpartum period

The evidence strongly supports switching from ramipril to enalapril or captopril for breastfeeding mothers requiring ACE inhibitor therapy, with calcium channel blockers and beta-blockers as excellent alternatives or add-on agents 3, 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.